Zelensky faces deepening political crisis as protests dig in
As protestors gathered in Ukraine for another demonstration against the ousting of a reformist defence minister, President Volodymyr Zelensky was facing one of the most urgent...
Tate brothers to fight 'politically motivated' UK extradition: lawyer
Influencer Andrew Tate and his brother Tristan will fight extradition to Britain on sex crime charges, their lawyer said Monday, slamming their recent arrest in...
Clinigen Appoints Greg Skalicky as Chief Executive Officer
Clinigen, the global pharmaceutical services company dedicated to accelerating access to critical medicines worldwide, today announced the appointment of Greg Skalicky as Group Chief Executive Officer, effective 20 July 2026. Greg succeeds Dr Varun Sethi, who...
Clinigen, the global pharmaceutical services company dedicated to accelerating access to critical medicines worldwide, today announced the appointment of Greg Skalicky as Group Chief Executive Officer, effective 20 July 2026. Greg succeeds Dr Varun Sethi, who...
Anglais
"The pain is immense," says Messi of World Cup defeat
Lionel Messi said on Monday that after Argentina's World Cup final loss "the pain is immense and it's going to take a long time for...
Chess legend Judit Polgar rejects becoming Hungary's president
Chess legend Judit Polgar on Monday turned down Hungarian Prime Minister Peter Magyar's offer to join his push to break with the Viktor Orban era...
Kinaxis Appoints Herb Yeh as Chief Financial Officer and Chief Strategy Officer
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today announced the appointment of Herb Yeh as Chief Financial Officer and Chief...
Kinaxis®
Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today announced the appointment of Herb Yeh as Chief Financial Officer and Chief...
Anglais
07/20/2026 20:00
Brenus Pharma Welcomes New European and Asia-Pacific Life Sciences Investors in Series A Extension
Brenus Pharma today announced an €11 million ($12.6M) extension to its Series A round, bringing total capital raised since inception to €38 million ($43.5M). This funding reflects strong execution across clinical, regulatory, and business development milestones, de-risking STC-1010 (NCT06934538): lead clinical-stage in-vivo immunotherapy for MSS mCRC, while positioning the company’s proprietary platform for multi-asset expansion. The round was supported by strong follow-on participation from ...
